High Grade Lymphomas

Our research and trials staff are dedicated and experienced professionals, interested in pushing the boundaries of our knowledge and testing new ideas in practical environments. Use the links below to jump to categorised trials.

Roche (GOYA)
Type: A phase III, multicentre, open-label, randomized trial
Eligibility: Previously untreated CD20-positive DLBCL Formalin-fixed paraffin-embedded tissue block Age > 18 years ECOG performance status of 0,1,or 2 LVEF > 50% on cardiac multuple-gated acquisition (MUGA) scan or cardiax endocardiogram
Study details: The primary objective of this study is to demonstrate superiority in PFS with G-CHOP compared with rituximab plus chemotherapy (R-CHOP) in previously untreated patients with CD20-positive DLBCL, based on investigator-assessed PFS.
R-CODOX-M/IVAC
Type: NCRI, multi-centre, phase II single arm study
Eligibility: Newly diagnosed CD20+ DLBCL in patients 18 – 60 years of age Stage II – IV disease with IPI score of 3 or more (i.e. high-intermediate or high)
Study details: This study assesses the benefit of using an intensified treatment approach in patients with high risk diffuse large B cell lymphoma. Patients will receive alternating courses of R-CODOX-M and R-IVAC for a total of 4 cycles (2 cycles each).
REMoDL-B (pending – GHH only)
Type: A randomised evaluation of Molecular guided therapy for Diffuse Large B-Cell Lymphoma with Bortezomib.
Eligibility: Histologically confirmed DLBCL, expressing CD20 Not previously treated for Lymphoma and fit enough to recieve combination chemoimmunotherapy with curative intent. Serum Creatinine <umol/L, Serum Billrubin <35umol/L and Transaminase <2.5 x upeer kimit of normal at the time of study entry, unless attributable to Lymphoma. Aged 18 or above. Cardiac function sufficient to tolerate 300mg/m2 of Doxorubicin.
Study details: To demonstrate superior clinical efficacy, as measured by progression-free survival (PFS), of Bortezomib in combination with Rituximab and CHOP (RB-CHOP) versus R-CHOP alone for the treatment of previously untreated patients with DLBCL. To assess weather the molecular phenotype, either activated by B-Cell (ABC) like or germinal centre B-Cell (GCB) like, of DLBCL determines the benefit from the addition of Bortezomib.